Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
58.14
+2.48 (+4.46%)
Streaming Delayed Price
Updated: 10:42 AM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
November 02, 2023
This stock could be a long-term winner, thanks to its game-changing technology.
Via
The Motley Fool
Why Are Stocks Up Today?
November 01, 2023
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
November 01, 2023
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.
Via
InvestorPlace
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
November 01, 2023
The agency could soon approve a potential cure for sickle cell disease .
Via
Investor's Business Daily
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
November 01, 2023
CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe.
Via
InvestorPlace
Exposures
Product Safety
AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today
October 31, 2023
Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CRISPR Therapeutics Stock: Bull vs. Bear
October 21, 2023
Here's the scoop on one of the most widely followed gene-editing stocks on the market.
Via
The Motley Fool
CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision
October 31, 2023
Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now.
Via
InvestorPlace
Exposures
Product Safety
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
October 27, 2023
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.
Via
InvestorPlace
Exposures
Product Safety
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
October 27, 2023
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next
Via
Benzinga
Exposures
Product Safety
Vertex Pharmaceuticals: Buy at the High?
October 26, 2023
Vertex shares have been flying high in recent times.
Via
The Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
October 26, 2023
These stocks make great bargains today.
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
October 25, 2023
Neither has performed well on the stock market this year.
Via
The Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less than $100
October 23, 2023
You can start with a small investment and win big over time.
Via
The Motley Fool
7 Biotech Stocks to Get In Now Before Investors Catch On
October 23, 2023
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
Via
InvestorPlace
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
October 21, 2023
Wood is going all in on gene editing.
Via
The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
October 17, 2023
Via
Benzinga
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
October 17, 2023
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...
Via
Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
October 17, 2023
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
October 16, 2023
This Wood favorite is heading for a big moment.
Via
The Motley Fool
2 Growth Stocks That Could Double Your Money, According to Wall Street
October 15, 2023
Find out why investment bank analysts are pounding the table on these stocks.
Via
The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
October 14, 2023
These two gene-editing stocks could be diamonds in the rough.
Via
The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
October 11, 2023
Via
Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
October 10, 2023
Via
Benzinga
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
October 10, 2023
Wood has outperformed the market so far this year.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.